Document Detail


Hirsutism - from diagnosis to use of antiandrogens.
MedLine Citation:
PMID:  24002408     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Hirsutism affects 5-8% of the whole female population. It results either from an increase in circulating androgen concentrations, an increase in the sensitivity of the pilosebaceous unit to normal androgen concentrations or a combination of these factors. Polycystic ovary syndrome is the underlying cause in the vast majority of patients with hirsutism; however, it should be kept in mind that it can only be diagnosed after exclusion of some other diseases such as non-classical congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia and acromegaly. The most important purpose for investigation is to identify those women with pathologies that can be potentially life threatening either due to their systemic effects or malignant potential. Specific causes of hirsutism such as Cushing's syndrome and adrenal/ovarian tumors should be treated by surgical excision of the tumor. In the other patients, pharmacological approach is the mainstay of the therapy. Antiandrogens can be competitive antagonists of the androgen receptor (spironolactone, cyproterone acetate, flutamide) or inhibitors of 5-α reductase, which decrease the conversion of testosterone to the more potent androgen 5-α dihydrotestosterone (finasteride). Antiandrogens should be used only after ensuring safe nonhormonal contraception to avoid fetal male pseudohermaphroditism in case of unplanned pregnancy.
Authors:
Kursad Unluhizarci; Zuleyha Karaca; Fahrettin Kelestimur
Related Documents :
25083888 - Polycystic ovary syndrome - phenotypes and diagnosis.
25489438 - Plasmapheresis: lifesaving treatment in severe cases of hellp syndrome.
23245558 - Short-lived corpora lutea syndrome in anoestrous ewes following 17β-oestradiol or map t...
25402738 - Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how ...
24156588 - Carpal tunnel syndrome in patient with hemihypertrophy: case report.
12398538 - Novel terpenoids from the formosan soft coral cespitularia hypotentaculata.
Publication Detail:
Type:  Journal Article     Date:  2012-10-18
Journal Detail:
Title:  Frontiers of hormone research     Volume:  40     ISSN:  1662-3762     ISO Abbreviation:  Front Horm Res     Publication Date:  2013  
Date Detail:
Created Date:  2013-09-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0320246     Medline TA:  Front Horm Res     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  103-14     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 S. Karger AG, Basel.
Affiliation:
Department of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insulin sensitizers in polycystic ovary syndrome.
Next Document:  Combined oral contraceptives in polycystic ovary syndrome - indications and cautions.